NYSE:BHC Bausch Health Companies (BHC) Stock Price, News & Analysis $6.21 +0.02 (+0.32%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$6.12▼$6.3350-Day Range$5.23▼$7.6252-Week Range$3.96▼$11.46Volume11.53 million shsAverage Volume3.13 million shsMarket Capitalization$2.24 billionP/E RatioN/ADividend YieldN/APrice Target$7.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Bausch Health Companies alerts: Email Address Bausch Health Companies MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside18.1% Upside$7.33 Price TargetShort InterestBearish5.59% of Float Sold ShortDividend StrengthN/ASustainability-1.42Upright™ Environmental ScoreNews Sentiment0.78Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth15.51%From $3.61 to $4.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.77 out of 5 starsMedical Sector202nd out of 910 stocksPharmaceutical Preparations Industry84th out of 426 stocks 3.0 Analyst's Opinion Consensus RatingBausch Health Companies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageBausch Health Companies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bausch Health Companies' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.59% of the float of Bausch Health Companies has been sold short.Short Interest Ratio / Days to CoverBausch Health Companies has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Bausch Health Companies has recently increased by 1.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBausch Health Companies does not currently pay a dividend.Dividend GrowthBausch Health Companies does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBausch Health Companies has received a 55.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Allergy eye drops", "Anti-diarrheal and intestinal anti-inflammatory medication (A07)", "Laxatives", and "Intraocular lenses" products. See details.Environmental SustainabilityThe Environmental Impact score for Bausch Health Companies is -1.42. Previous Next 2.1 News and Social Media Coverage News SentimentBausch Health Companies has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Bausch Health Companies this week, compared to 3 articles on an average week.Search InterestOnly 33 people have searched for BHC on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Bausch Health Companies to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bausch Health Companies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.12% of the stock of Bausch Health Companies is held by insiders.Percentage Held by Institutions78.65% of the stock of Bausch Health Companies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bausch Health Companies' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Bausch Health Companies are expected to grow by 15.51% in the coming year, from $3.61 to $4.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bausch Health Companies is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bausch Health Companies is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Bausch Health Companies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Bausch Health Companies Stock (NYSE:BHC)Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Read More BHC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BHC Stock News HeadlinesSeptember 2, 2024 | insidermonkey.comBausch Health Companies Inc. (BHC): Among Billionaire Carl Icahn’s Top Stock PicksAugust 28, 2024 | americanbankingnews.comQ3 2024 Earnings Estimate for Bausch Health Companies Inc. Issued By Zacks Research (NYSE:BHC)September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 20, 2024 | insidermonkey.comBausch Health Companies Inc. (BHC): One of the Best Canadian Stocks Under $20August 9, 2024 | msn.comTD COWEN Downgrades Bausch Health Companies (BHC)August 2, 2024 | markets.businessinsider.comBausch Health Companies: Sell Rating Reiterated Amid Spin-Off Uncertainties and Financial ConcernsAugust 2, 2024 | msn.comBausch Health Companies Inc. (NYSE:BHC) Q2 2024 Earnings Call TranscriptAugust 1, 2024 | seekingalpha.comBausch Health Companies (BHC) Q2 2024 Earnings Call TranscriptSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 1, 2024 | seekingalpha.comBausch Health Companies Inc. 2024 Q2 - Results - Earnings Call PresentationJuly 26, 2024 | theglobeandmail.comClosing Bell: Bausch Health Companies Inc up on Thursday (BHC)July 24, 2024 | investopedia.comBausch Health Stock Swings Wildly as it Addresses Report It's Considering BankruptcyJuly 24, 2024 | investorplace.comBHC Stock Plunges as Bausch Health Appears on the Brink of BankruptcyJuly 24, 2024 | reuters.comBausch Health denies report of bankruptcy filingJuly 24, 2024 | finance.yahoo.comNanotechnology in medicine: Who are the leading public companies?July 24, 2024 | seekingalpha.comBausch Health plunges on report of potential prepackaged Chapter 11 bankruptcyJuly 20, 2024 | ca.investing.comTSX Stung, Like U.S. BrethrenJuly 19, 2024 | nz.finance.yahoo.comBausch Health Companies Inc. (BVF.F)See More Headlines Receive BHC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:BHC CUSIPN/A CIK885590 Webwww.bauschhealth.com Phone(514) 744-6792Fax514-744-6272Employees20,270Year FoundedN/APrice Target and Rating Average Stock Price Target$7.33 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+18.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.24) Trailing P/E RatioN/A Forward P/E Ratio1.72 P/E GrowthN/ANet Income$-592,000,000.00 Net Margins-5.12% Pretax Margin-3.85% Return on Equity-742.06% Return on Assets4.94% Debt Debt-to-Equity RatioN/A Current Ratio1.19 Quick Ratio0.82 Sales & Book Value Annual Sales$9.20 billion Price / Sales0.24 Cash Flow$7.57 per share Price / Cash Flow0.82 Book Value($0.63) per share Price / Book-9.86Miscellaneous Outstanding Shares360,990,000Free Float331,678,000Market Cap$2.24 billion OptionableOptionable Beta0.77 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Thomas J. Appio (Age 62)CEO & Director Comp: $2.74MMr. John S. Barresi (Age 51)Senior VP, Controller, Chief Accounting Officer & Interim CFO Comp: $796.8kMs. Seana Carson (Age 51)Executive VP & General Counsel Comp: $872.65kMr. Mirza DautbegovicSenior VP & COOMr. Josh CoyleSenior Vice President of Sales & SalixMs. Kathleen FitzpatrickSenior VP & Chief HR OfficerDr. Tage Ramakrishna M.D. (Age 50)Chief Medical Officer and President of R&D Mr. Jeff HartnessExecutive VP of Market Access, Commercial Operations, Neurology, Generics & Government AffairsDr. Graham JacksonSenior VP & Chief Quality OfficerMr. Cees HeimanSenior Vice President of Europe & CanadaMore ExecutivesKey CompetitorsSummit TherapeuticsNASDAQ:SMMTLegend BiotechNASDAQ:LEGNIntra-Cellular TherapiesNASDAQ:ITCIElanco Animal HealthNYSE:ELANLantheusNASDAQ:LNTHView All CompetitorsInsiders & InstitutionsClearline Capital LPBought 987,206 shares on 8/16/2024Ownership: 0.273%Mackenzie Financial CorpBought 1,252,834 shares on 8/15/2024Ownership: 0.660%The Manufacturers Life Insurance Company Bought 4,944 shares on 8/15/2024Ownership: 0.068%Maverick Capital Ltd.Bought 230,431 shares on 8/15/2024Ownership: 0.064%SIG North Trading ULCSold 74,600 shares on 8/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions BHC Stock Analysis - Frequently Asked Questions How have BHC shares performed this year? Bausch Health Companies' stock was trading at $8.02 at the beginning of the year. Since then, BHC stock has decreased by 22.6% and is now trading at $6.21. View the best growth stocks for 2024 here. How were Bausch Health Companies' earnings last quarter? Bausch Health Companies Inc. (NYSE:BHC) posted its earnings results on Thursday, August, 1st. The company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.09. The company had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.33 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative trailing twelve-month return on equity of 742.06%. What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO? 43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are Bausch Health Companies' major shareholders? Top institutional investors of Bausch Health Companies include National Bank of Canada FI (4.34%), Lombard Odier Asset Management USA Corp, Dimensional Fund Advisors LP (0.88%) and Mackenzie Financial Corp (0.66%). Insiders that own company stock include Seana Carson, Robert Spurr, Joseph F Gordon and Steven D Miller. View institutional ownership trends. How do I buy shares of Bausch Health Companies? Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bausch Health Companies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX) and Alibaba Group (BABA). This page (NYSE:BHC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch Health Companies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bausch Health Companies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.